This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers
by Zacks Equity Research
Butterfly Network targets a 2026 Beam Steering API, opening core imaging to developers and enabling AI tools in Butterfly Garden.
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
by Zacks Equity Research
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
RBOT Enters Strategic Software Partnership to Streamline Development
by Zacks Equity Research
Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical
by Zacks Equity Research
Veracyte stands out in a pressured medical instruments industry as genAI adoption and rising sales forecasts fuel investor interest.
3 Medical Instrument Stocks to Counter Industry Woes Using GenAI
by Moumi Mondal
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
by Zacks Equity Research
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
Is This the Right Time to Add Veracyte Stock to Your Portfolio?
by Zacks Equity Research
VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.
HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases
by Zacks Equity Research
Hologic shares dip as the company unveils new study data showing its Genius AI mammography flags 32% of previously missed breast cancer cases.
ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries
by Zacks Equity Research
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
by Zacks Equity Research
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.